Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial

BACKGROUND: Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP therapy in COVID-19 progression. METHODS AND FINDINGS: The study was an op...

Descripción completa

Detalles Bibliográficos
Autores principales: Balcells, María Elvira, Rojas, Luis, Le Corre, Nicole, Martínez-Valdebenito, Constanza, Ceballos, María Elena, Ferrés, Marcela, Chang, Mayling, Vizcaya, Cecilia, Mondaca, Sebastián, Huete, Álvaro, Castro, Ricardo, Sarmiento, Mauricio, Villarroel, Luis, Pizarro, Alejandra, Ross, Patricio, Santander, Jaime, Lara, Bárbara, Ferrada, Marcela, Vargas-Salas, Sergio, Beltrán-Pavez, Carolina, Soto-Rifo, Ricardo, Valiente-Echeverría, Fernando, Caglevic, Christian, Mahave, Mauricio, Selman, Carolina, Gazitúa, Raimundo, Briones, José Luis, Villarroel-Espindola, Franz, Balmaceda, Carlos, Espinoza, Manuel A., Pereira, Jaime, Nervi, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929568/
https://www.ncbi.nlm.nih.gov/pubmed/33657114
http://dx.doi.org/10.1371/journal.pmed.1003415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929568/
https://www.ncbi.nlm.nih.gov/pubmed/33657114
http://dx.doi.org/10.1371/journal.pmed.1003415

Ejemplares similares